KALA BIO

KALA

Market cap $10.2M

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

Always be cautious before investing in a penny stock. While some will turn out to be explosive winners, like Advanced Micro Devices, others turn out to be expensive duds.

Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kala Bio (KALA -2.19%), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 (GAAP).

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 --

ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday, August 13, 2025 at 7:00 a.m. ET. KALA management will also participate in a panel discussion titled “Novel Treatments for Front-of-the-Eye Indications” on Wednesday, August 13, 2025 at 1:00 p.m. ET. Management will be available for virtual one-on-one meetings throughout the conference.

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results --

ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025.